Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 12178.144 | 0.2825 | -0.5971 | 0.7891 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 12291.168 | 0.8350 | 0.3355 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 12291.168 | 0.7698 | 0.1135 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 12291.168 | 0.7568 | 0.0716 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 12291.168 | 0.5914 | -0.3831 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 12291.168 | 0.6195 | -0.3156 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 12291.168 | 0.5823 | -0.4042 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 12291.168 | 0.5727 | -0.4259 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12291.168 | 0.5107 | -0.5557 | 0.4466 | |
BT-474 | HER2amp | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 12291.168 | 0.0116 | -0.9999 | 0.4466 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10696.144 | 0.9333 | 0.7160 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10696.144 | 0.8175 | 0.2786 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10696.144 | 0.6802 | -0.1497 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10696.144 | 0.6632 | -0.1963 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10696.144 | 0.6375 | -0.2637 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10696.144 | 0.6289 | -0.2856 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10696.144 | 0.5930 | -0.3730 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10696.144 | 0.6010 | -0.3541 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 10696.144 | 0.0137 | -0.9999 | 0.4505 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 11855.144 | 0.9434 | 0.8137 | 0.5961 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 11855.144 | 0.8072 | 0.3963 | 0.5961 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 11855.144 | 0.7403 | 0.2077 | 0.5961 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 11855.144 | 0.7017 | 0.1039 | 0.5961 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 11855.144 | 0.7026 | 0.1063 | 0.5961 | |
BT-483 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 11855.144 | 0.6533 | -0.0209 | 0.5961 |